Literature DB >> 1103277

Surgical treatment of eyelid cancer with special reference to tarsoconjunctival flaps. A follow-up on 193 patients.

H Holmström, L Bartholdson, B Johanson.   

Abstract

203 cancers of the eyelid were operated on in 193 patients. 65% of the tumours occurred in males and the peak incidence was at 75 years. 60% afflicted the lower eyelids and 21% the medial canthi. Basal cell carcinoma were found in 182 specimens and spinocellular carcinoma in only 8. Malignant melanoma, Meibomian gland carcinoma and rhabdomyosarcoma appeared each in one patient, the latter representing the only fatal case in eyelid cancer. All cancers were excised with a free margin around 5 mm. The standard procedures of reconstruction of the eyelid defect were a fullthickness skin graft in cases where conjunctiva and tarsus could be preserved (97 cases), and a tarsoconjunctival flap in full-thickness defects of the lower eyelid (58 cases). Other methods used were wedge excision and direct approximation in very small lesions involving the lid margin, an infratarsal island flap from the lower eyelid for medium-sized to large defects in the upper lid and a forehead or scalp flap after exenteration of the orbit. 18/203 cancers recurred and 12 of these were primarily regarded as radically treated. Seven of the latter were reoperated after more than 3 years and may in fact be new tumours. No metastases were found. The various reconstructive procedures are discussed in detail

Entities:  

Mesh:

Year:  1975        PMID: 1103277     DOI: 10.3109/02844317509022775

Source DB:  PubMed          Journal:  Scand J Plast Reconstr Surg        ISSN: 0036-5556


  3 in total

1.  Basal cell carcinoma in the eyelid region.

Authors:  J R Collin
Journal:  Br J Ophthalmol       Date:  1976-12       Impact factor: 4.638

2.  Surgical management of carcinoma of eyelids and periorbital skin.

Authors:  H Mehta
Journal:  Br J Ophthalmol       Date:  1979-08       Impact factor: 4.638

3.  Spontaneous reformation of lower eyelid.

Authors:  H K Mehta
Journal:  Br J Ophthalmol       Date:  1981-03       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.